01855nas a2200397   4500000000100000008004100001260001300042653001500055653001000070653002600080653001000106653002100116653001100137653001100148653002100159653001400180653001100194653002500205653001200230653000900242653001900251653001600270653002500286653001500311653002400326653003000350653002000380100001200400700001200412700001600424245017600440300001000616490000700626520081000633022001401443       1995                            d  c1995 Dec10aAdolescent10aAdult10aAntibodies, Bacterial10aChild10aChild, Preschool10aFemale10aHumans10aImmunoglobulin M10aIndonesia10aInfant10aLatex Fixation Tests10aleprosy10aMale10aMass Screening10aMiddle Aged10aMycobacterium leprae10aPrevalence10aProspective Studies10aSeroepidemiologic Studies10aSuburban Health1 aHatta M1 aIzumi S1 aKlatser P R00aEvaluation of the Mycobacterium leprae particle agglutination (MLPA) test as a tool in the epidemiology of leprosy in high prevalence village in South Sulawesi, Indonesia.  a631-50 v263 a<p>This study reports on the usefulness of an IgM phenolic glycolipid-1 (PGL-1) Mycobacterium leprae particle agglutination (MLPA) test for serodiagnosis of leprosy in a prospective longitudinal community survey in a high prevalence village in South Sulawesi, Indonesia, IgM PGL-1 MLPA has simple and limited value as a screening method for detection of transmission of leprosy in the community. Many normal persons in the community in a high prevalence area had increased IgM anti PGL-1 antibodies, presumably as a consequence of early subclinical infection. In conclusion, this study demonstrated that the MLPA test can only reliably detect anti-PGL-1 antibodies in the community and may be useful for follow-up study of subclinical infection of leprosy among individuals living the an endemic area.</p>  a0125-1562